Unlocking FDA Drug Approval: A Comprehensive Training Course
The FDA's drug approval process is a complex journey, and staying updated is crucial for pharmaceutical success. ResearchAndMarkets.com introduces a 2-day virtual training course on FDA drug approval, a must-attend for industry professionals.
This course, taking place on February 23rd and 24th, 2026, is designed to demystify the US regulatory landscape for pharmaceutical companies, especially those targeting the lucrative US market. With the US leading in pharmaceutical sales, understanding FDA procedures is essential for a smooth submission process.
Here's a glimpse into what you can expect:
- Navigating the Submission Process: Learn the ins and outs of submitting INDs, NDAs, ANDAs, and 505(b)(2) applications. Understand the FDA's organizational structure and its review processes, and stay ahead with the latest changes.
- Focus on Innovation: While covering generic and over-the-counter drugs, the course emphasizes innovative manufacturers' interests, ensuring a comprehensive understanding of the FDA's approach.
- Interactive Learning: Engage in discussions with an expert trainer and fellow delegates. A practical workshop session will ensure you leave with actionable insights.
Benefits of Attending:
- Stay updated with the FDA's latest regulatory requirements for drug development.
- Grasp the strategic regulatory needs of the FDA.
- Ensure compliance with FDA mandates for NDAs, ANDAs, and 505(b)(2).
- Discuss industry trends with experts and enhance your communication with the FDA.
Who Should Join?
This course is tailored for professionals preparing US registration documents (INDs, NDAs, Biologics License Applications, etc.), regulatory affairs teams, legal advisors, and anyone guiding companies on US market drug development strategies.
What You'll Achieve:
- CPD: 12 hours of professional development
- A certificate of completion, recognizing your expertise in FDA drug approval processes
Key Topics Unveiled:
Day 1:
- Pharmaceutical Medicine and Documents: Explore the role of regulatory affairs and the Common Technical Document (CTD).
- FDA History and Organization: Dive into FDA centers, the structure of CDER and CBER, and their differences.
- Legal Basis: Understand the 21st Century Cures Act, patent exclusivity, PDUFA, GDUFA, and BsUFA.
- Application and Submission Types: From Investigational New Drugs (INDs) to Biologics License Applications (BLAs), grasp the various application types.
- Refusal to File: Learn why applications are refused and navigate the regulatory process.
- Investigational New Drug (IND) Applications: A deep dive into the content of an IND.
- Expedited Programs: Discover how to get products to market faster with Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review designations.
- FDA Meetings and Documentation: Understand FDA communication, meeting types, and procedures.
- CTD Content: Explore lean authoring for document reuse and review different modules.
Day 2:
- CTD Content: M3, M4, and M5 modules with corresponding M2 sections.
- Submission Format and Methods: Study tagging files, datasets, case report forms, and Bioresearch monitoring (BIMO) clinical data.
- US Amendment Procedures: Understand annual reports and minor/major changes.
- US vs. EU Comparison: Explore dossier content and procedural differences.
- Case Study: Apply your knowledge to a real-world scenario.
Meet the Expert:
Andrew Willis, an independent consultant, brings a wealth of experience. With a background in Catalent Pharma Solutions as VP Regulatory Affairs & Consulting Services, he led a team of regulatory affairs experts. His journey began as a Chemist, evolving into a research role at Parke Davis. With 28 years in pharmaceuticals, he's an authority on sterile, solid oral, inhalation, topical, and biotech products. His expertise includes managing complex regulatory projects and successful MAA submissions, making him the ideal guide through the FDA approval process.
About ResearchAndMarkets.com:
ResearchAndMarkets.com is your gateway to global market insights. We provide the latest market research reports and data, keeping you informed about international markets, industries, and trends.
But here's where it gets intriguing: How does the FDA's process compare to other global regulatory bodies? Are there alternative approaches to drug approval that could be more efficient? Share your thoughts and experiences in the comments below! Engage in a discussion that could shape the future of pharmaceutical regulations.
